Skip Navigation


Annals of Oncology Advance Access originally published online on September 11, 2009
Annals of Oncology 2009 20(11):1900-1901; doi:10.1093/annonc/mdp448
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/11/1900    most recent
mdp448v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hentrich, M.
Right arrow Articles by Gerl, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hentrich, M.
Right arrow Articles by Gerl, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor

The first 10% of the full text of this article appears below.

Testicular germ-cell tumors (GCT) occur more frequently in human immunodeficiency virus (HIV)-infected patients than in the general population [1]. Initial studies indicated that the outcome of patients with HIV-related GCT was poor compared with those without HIV infection [2, 3]. Nevertheless, since the introduction of highly active antiretroviral therapy the outcome has improved due to a decrease in HIV-related deaths [4].

Most patients with GCT who achieve a complete response to initial chemotherapy are cured, with relapses occurring . . . [Full Text of this Article]

M. Hentrich1,*, X. Schiel1, A. Niedermeier2, L. Lutz1, R. Rupec2, C. Stief3, J. Bogner4, M. Karthaus1 and A. Gerl5

1 Department of Hematology and Oncology, Harlaching Hospital, Academic Teaching Hospital of Ludwig-Maximilians-University
2 Department of Dermatology and Allergology, Ludwig-Maximilians-University
3 Department of Urology, Ludwig-Maximilians-University—Großhadern
4 Department of Medicine, Ludwig-Maximilians-University—Innenstadt
5 Private Practice of Oncology, Munich, Germany

* (E-mail: tumorzentrum.hentrich@khmh.de)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?